Anzeige
Meldung des Tages: SEAS meldet US-Compliance: Kobalt-Ziele in zwei Ozeanen im Fokus

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Medikamente Land:  Frankreich
70,20 €
-0,90 €
-1,27%
17:33:33 Uhr
Depot/Watchlist
Marktkapitalisierung *
87,58 Mrd. €
Streubesitz
43,71%
KGV
8,28
Dividende
3,92 EUR
Dividendenrendite
5,29%
Nachhaltigkeits-Score
69 %
Index-Zuordnung
Euro Stoxx 50
Weiter abwärts? Short handeln - Jetzt mit Faktor 2,00: VK6LQM
Werbung

Ad-hocs

29.04.26 - GlobeNewswire
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026
24.04.26 - GlobeNewswire
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue
23.04.26 - GlobeNewswire
Press Release: Q1 2026: double-digit sales and business EPS growth
Q1 2026: double-​digit sales and business EPS growth
22.04.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
22.04.26 - GlobeNewswire
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to ...
22.04.26 - GlobeNewswire
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to ...
18.04.26 - GlobeNewswire
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-​to-head study First head-​to-head, double-​blind, randomized phase 4 study ...
13.04.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
31.03.26 - GlobeNewswire
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
Sanofi’s Rezurock approved in the EU to treat chronic graft-​vs-host disease
28.03.26 - GlobeNewswire
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-​breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 ...
27.03.26 - GlobeNewswire
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
24.03.26 - GlobeNewswire
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire
24.03.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-​to-severe patients was based on ...
18.03.26 - GlobeNewswire
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi’s  venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
05.03.26 - GlobeNewswire
Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi’s Board of Directors proposes the appointment of Christel  Heydemann as an independent director Paris, March  5 , 202 6 . The Board of Directors of Sanofi has decided to ...
04.03.26 - GlobeNewswire
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an ...
02.03.26 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third ...
27.02.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, ...
24.02.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
17.02.26 - GlobeNewswire
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026 . Sanofi announces today the ...

Newssuche

Videos

newspaper
28.09.26 -5,28%
Technical Trading Montags Schwäche nutzen
Gold Short Typ: Turbo Open End WKN: BD732R Hebel:43,25 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Weitere Videos ❯

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren

Wir sind wieder bei den Zertifikate Awards dabei!

Auch in diesem Jahr nimmt ARIVA.DE wieder an den Zertifikate Awards teil. Stimme jetzt für deine Favoriten ab — deine Stimme zählt!

✈️
Zu gewinnen
Eine Reise nach Berlin

Unter allen Teilnehmerinnen und Teilnehmern wird mit etwas Glück eine Reise nach Berlin verlost. Danke, dass du dabei bist!

Jetzt abstimmen →